Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis

QJM: An International Journal of Medicine

Volumn 100, Issue 4, 2007, Pages 193-201

  Niewold, T B ^a   Harrison, M J ^a   Paget, S A ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPERINUCLEAR FACTOR; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; KERATIN ANTIBODY; RHEUMATOID FACTOR;

ANTIBODY DETECTION; CIGARETTE SMOKING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; HEPATITIS C; HIGH RISK PATIENT; HUMAN; IMMUNOASSAY; IMMUNOPATHOLOGY; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MAJOR HISTOCOMPATIBILITY COMPLEX; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 34447316727     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm015     Document Type: Review

References (50)

1. de Vries-Bouwstra JKD, Breedveld BAC, Ferdinand C. Biologics in early rheumatoid arthritis. Rheum Dis Clin North Am 2005; 31 745-62.
2. Dorner T, et al. Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16:246-53.
3. Arnett FC, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
4. Nienhuis RL, Mandema E. A New Serum Factor in Patients with Rheumatoid Arthritis; the Antiperinuclear Factor. Ann Rheum Dis 1964; 23 302-5.
5. Young BJ, et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979; 2:97-9.
6. Simon M, et al. The cytokeratin filament-aggregating protein filaggrin is the target of the so-called 'antikeratin antibodies,' autoantibodies specific for rheumatoid arthritis. J Clin Invest 1993; 92:1387-93.
7. Sebbag M, et al. The antiperinuclear factor and the so-called antikeratin antibodies are the same rheumatoid arthritis-specific autoantibodies. J Clin Invest 1995; 95:2672-9.
8. Schellekens GA, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998; 101:273-81.
9. Girbal-Neuhauser E, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of filaggrin by deimination of arginine residues. J Immunol 1999; 162:585-94.
10. Vossenaar ER, et al. PAD, a growing family of citrullinating enzymes: Genes, features and involvement in disease. Bioessays 2003; 25:1106-18.
11. Schellekens GA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43:155-63.
12. van Gaalen FA, Visser H, Huizinga TWJ. A comparison of the diagnostic accuracy and prognostic value of the first and second anti-cyclic citrullinated peptides (CCP1 and CCP2) autoantibody tests for rheumatoid arthritis. Ann Rheum Dis 2005; 64:1510-12.
13. Bizzaro N, et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001; 47 1089-93.
14. Bas S, et al. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003; 42:677-80.
15. Zeng X, et al. Diagnostic value of anti-cyclic citrullinated Peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003; 30:1451-5.
16. Lee DM, Schur PH. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003; 62:870-4.
17. Suzuki K, et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003; 32:197-204.
18. Vallbracht I, et al. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Ann Rheum Dis 2004; 63 1079-84.
19. De Rycke L, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004; 63:1587-93.
20. Jansen AL, et al. Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002; 29:2074-6.
21. Saraux A, et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003; 30:2535-9.
22. van Gaalen FA, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study. Arthritis Rheum 2004; 50:709-15.
23. Vittecoq O, et al. Autoantibodies recognizing citrullinated rat filaggrin in an ELISA using citrullinated and non-citrullinated recombinant proteins as antigens are highly diagnostic for rheumatoid arthritis. Clin Exp Immunol 2004; 135:173-80.
24. Soderlin MK, et al. Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: Relation to diagnosis and disease activity. Scand J Rheumatol 2004; 33:185-8.
25. Rantapaa-Dahlqvist S, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003; 48:2741-9.
26. Nielen MM, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-6.
27. Mandl LA, Chibnik L, Schur P, Karlson EW. Anti-cyclic citrullinated peptide (Anti-CCP) antibodies are strongly associated with risk of rheumatoid arthritis after adjusting for hormonal and behavioral factors. Arthritis Rheum 2005; 52(suppl.):S732.
28. Visser H, et al. How to diagnose rheumatoid arthritis early: A prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002; 46:357-65.
29. Pinheiro GC, et al. Anti-cyclic citrullinated peptide antibodies in advanced rheumatoid arthritis. Ann Intern Med 2003; 139 234-5.
30. Kastbom A, et al. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004; 63:1085-9.
31. Forslind K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: Role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004; 63 1090-5.
32. Stolt P, et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: Results from a population based case-control study, using incident cases. Ann Rheum Dis 2003; 62:835-41.
33. Kroot EJ, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000; 43:1831-5.
34. Vencovsky J, et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003; 62:427-30.
35. Alessandri C, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004; 63:1218-21.
36. Vander Cruyssen B, et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005; 64:1145-9.
37. Alenius GM, Berglin E, Rantapaa Dahlqvist S. Antibodies against cyclic citrullinated peptide (CCP) in psoriatic patients with or without manifestation of joint inflammation. Ann Rheum Dis 2005; 65 398-400.
38. Mediwake R, et al. Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001; 60:67-8.
39. Bombardieri M, et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004; 6:R137-41.
40. Vossenaar ER, et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004; 50:3485-94.
41. Vossenaar ER, et al. Citrullination of synovial proteins in murine models of rheumatoid arthritis. Arthritis Rheum 2003; 48 2489-500.
42. Suzuki A, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395-402.
43. Barton A, et al. Investigation of polymorphisms in the PADI4 gene in determining severity of inflammatory polyarthritis. Ann Rheum Dis 2005; 64:1311-15.
44. van Gaalen FA, et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis. Arthritis Rheum 2004; 50 2113-21.
45. Berglin E, et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004; 6:R303-8.
46. Irigoyen P, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: Contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005; 52:3813-18.
47. Goldbach-Mansky R, et al. Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res 2000; 2:236-43.
48. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205-13.
49. Hill JA, et al. Cutting edge: The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171:538-41.
50. Klareskog L, et al. A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38-46.